Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Indivior Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Indivior Pharmaceuticals, Inc.’s stock price such as:

• Indivior Pharmaceuticals, Inc.’s current stock price and volume
• Why Indivior Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for INDV from analysts
• INDV’s stock price momentum as measured by its relative strength

About Indivior Pharmaceuticals, Inc. (INDV)

Before we jump into Indivior Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Want to learn more about Indivior Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Indivior Pharmaceuticals, Inc..

Indivior Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Indivior Pharmaceuticals, Inc.’s stock price was $40.010.

Indivior Pharmaceuticals, Inc. is down 0.52% from its previous closing price of $40.220.

During the last market session, Indivior Pharmaceuticals, Inc.’s stock traded between $38.630 and $40.300. Currently, there are approximately 124.00 million shares outstanding for Indivior Pharmaceuticals, Inc..

Indivior Pharmaceuticals, Inc.’s price-earnings (P/E) ratio is currently at 20.5, which is low compared to the Pharmaceuticals industry median of 20.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Indivior Pharmaceuticals, Inc. Stock Price History

Indivior Pharmaceuticals, Inc.’s (INDV) price is currently down 2.49% so far this month.

During the month of July, Indivior Pharmaceuticals, Inc.’s stock price has reached a high of $41.880 and a low of $38.560.

Over the last year, Indivior Pharmaceuticals, Inc. has hit prices as high as $42.810 and as low as $19.750. Year to date, Indivior Pharmaceuticals, Inc.’s stock is up 11.51%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Indivior Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Indivior Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Indivior Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Indivior Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Indivior Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Indivior Pharmaceuticals, Inc. (INDV) by visiting AAII Stock Evaluator.

Relative Price Strength of Indivior Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Indivior Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 12.27%, which translates to a Momentum Score of 85 and is considered to be Very Strong.

Want to learn more about how Indivior Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Indivior Pharmaceuticals, Inc. Stock Price: Bottom Line

As of July 31, 2026, Indivior Pharmaceuticals, Inc.’s stock price is $40.010, which is down 0.52% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Indivior Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.